Exicure(US:XCUR)2025-08-08 20:11Financial Performance - The net loss for Q2 2025 was $2.6 million, compared to a net loss of $0.6 million in Q2 2024, indicating an increase in loss of approximately 333.3%[7] - The company reported no revenue for Q2 2025, consistent with Q2 2024, while total revenue for the six months ended June 30, 2025, remained at $0[17] - The company recognized a loss of $60,000 from the sale of fixed assets related to GPCR USA[6] Cash and Liquidity - Cash and cash equivalents decreased to $7.9 million as of June 30, 2025, from $12.5 million as of December 31, 2024, representing a decline of 36.8%[3] - Management indicated that existing cash is insufficient to fund operations, necessitating substantial additional financing in the short term[8] Expenses - Research and development expenses for Q2 2025 were $0.9 million, compared to $0 for Q2 2024, marking a significant increase due to the acquisition of GPCR Therapeutics USA Inc.[4] - General and administrative expenses rose to $1.5 million in Q2 2025, up from $1.2 million in Q2 2024, reflecting an increase of 25% primarily due to costs associated with the GPCR USA acquisition[5] Assets and Liabilities - Total assets increased to $18.7 million as of June 30, 2025, from $15.1 million as of December 31, 2024, representing a growth of 24.3%[14] - Total liabilities rose to $9.9 million as of June 30, 2025, compared to $8.3 million as of December 31, 2024, an increase of 19.5%[14] Strategic Direction - The company is exploring strategic alternatives to maximize stockholder value following its restructuring and acquisition activities[10]